While the reported CK/Crn dynamics suggest therapy response in our nusinersen‐treated cohort, Tiziano et al. reported an increase of CK associated with increasing SMN2‐full length transcripts in SMA patients treated with salbutamol in a clinical trial.45 This evidence concerns the gene SMN2 and proximal spinal muscular atrophy.